• TAI-1: A Potent Small Molecule Hec1 Inhibitor for Cancer ...

  2026-03-24

  TAI-1 stands out as a first-in-class small molecule Hec1 inhibitor with exceptional potency and specificity, enabling advanced mechanistic studies in cancer cell mitosis and apoptosis. Its high selectivity, synergistic action with leading chemotherapeutics, and robust in vivo efficacy make it a trusted tool for accelerating translational oncology research.

• ONX-0914: The Selective Immunoproteasome Inhibitor for Au...

  2026-03-23

  ONX-0914 (PR-957) stands out as a potent, highly selective immunoproteasome inhibitor, enabling precise modulation of immune responses in autoimmune and inflammatory disease research. Its robust inhibition of LMP7-driven cytokine production unlocks reproducibility and specificity in both cell-based and in vivo experimental workflows. Leverage ONX-0914 to dissect immune mechanisms, troubleshoot cytokine assays, and advance translational models with confidence.

• IWP-2: Small Molecule Wnt Pathway Antagonist in Cancer Re...

  2026-03-23

  IWP-2 stands out as a highly potent Wnt production inhibitor, offering nanomolar efficacy for robust and reproducible pathway interrogation in both in vitro and in vivo cancer research models. This article details experimental workflows, advanced applications, and troubleshooting strategies that leverage IWP-2’s unique advantages, empowering researchers to dissect Wnt/β-catenin signaling with unprecedented precision.

• Scenario-Driven Solutions with Pexidartinib (PLX3397) in ...

  2026-03-22

  This article provides biomedical researchers and laboratory professionals with scenario-driven, evidence-based guidance for using Pexidartinib (PLX3397), SKU B5854, in cell viability, proliferation, and cytotoxicity assays. It addresses common experimental pitfalls and demonstrates how this selective CSF1R inhibitor enables robust data acquisition and reproducible macrophage modulation. Leverage these insights to optimize your workflows and maximize the reliability of your tumor microenvironment studies.

• Merimepodib (VX-497): Selective Oral IMPDH Inhibitor for ...

  2026-03-21

  Merimepodib (VX-497) is a potent, orally bioavailable, noncompetitive IMPDH inhibitor that disrupts guanine nucleotide biosynthesis. It demonstrates robust efficacy in inhibiting lymphocyte proliferation, immune response modulation, and antiviral activity against diverse viruses, supporting its role in cancer chemotherapy and viral infection research.

• WZ4003: Selective NUAK1/2 Inhibitor for Advanced Cell Sig...

  2026-03-20

  WZ4003 stands as a highly selective NUAK kinase inhibitor, enabling precise modulation of LKB1-activated signaling pathways in both cancer and neurodegeneration models. This article provides actionable workflows, troubleshooting insights, and real-world data to empower researchers leveraging WZ4003 in cell migration, proliferation, and tau phosphorylation studies.

• WM-8014: Selective KAT6A/B Inhibitor for Epigenetic and C...

  2026-03-20

  WM-8014 is a highly potent, selective, and reversible histone lysine acetyltransferase inhibitor targeting KAT6A and KAT6B. This compound enables precise modulation of oncogene-induced senescence in cancer biology research, acting via competitive inhibition at the acetyl-CoA binding site with nanomolar potency.

• WZ4003: A Selective NUAK1/2 Inhibitor for Advanced Cancer...

  2026-03-19

  WZ4003 empowers researchers with precise NUAK kinase inhibition, enabling robust studies in cancer biology and neurodegeneration. Its selectivity and proven performance in cell migration, proliferation, and tau phosphorylation make it a cornerstone for dissecting LKB1-activated NUAK signaling. Discover optimized protocols, troubleshooting strategies, and future directions for leveraging this advanced chemical probe from APExBIO.

• 7ACC2: Carboxycoumarin MCT1 Inhibitor Transforming Cancer...

  2026-03-19

  7ACC2 stands out as a dual-action carboxycoumarin MCT1 inhibitor, blocking both monocarboxylate transporter 1 and mitochondrial pyruvate transport for unparalleled control over cancer metabolism research. Its potent inhibition of lactate uptake and demonstrable tumor growth delay empower researchers to dissect metabolic vulnerabilities and advance immunometabolic strategies.

• U0126-EtOH: Selective MEK1/2 Inhibitor for MAPK/ERK Pathw...

  2026-03-18

  U0126-EtOH empowers researchers with precise MEK1/2 inhibition, enabling robust MAPK/ERK pathway modulation for neuroprotection, cancer, and inflammation models. Its high selectivity and proven efficacy streamline advanced workflows and troubleshooting, setting a new standard for oxidative stress and immune response research.

• IWP-L6: Precision Porcupine Inhibition for Wnt Signaling ...

  2026-03-18

  Unlock reproducible Wnt pathway modulation with IWP-L6, a sub-nanomolar Porcupine inhibitor trusted by leading developmental and cancer biology labs. This guide delivers applied workflows, troubleshooting insights, and advanced experimental use-cases that set APExBIO's IWP-L6 apart for precision control in Wnt signaling research.

• PKM2 Inhibitor (Compound 3k): Redefining Tumor Metabolism...

  2026-03-17

  Explore how PKM2 inhibitor (compound 3k) revolutionizes tumor cell specific PKM2 targeting and aerobic glycolysis disruption. Dive deep into its mechanistic insights, unique in vivo data, and emerging roles beyond oncology in this advanced guide.

• ONX-0914: Selective Immunoproteasome Inhibitor for Autoim...

  2026-03-17

  ONX-0914 (PR-957) stands apart as a gold-standard selective immunoproteasome inhibitor, enabling precise modulation of immune responses in autoimmune, inflammatory, and infectious disease models. From cell-based cytokine blockade to in vivo disease attenuation, this LMP7 inhibitor empowers researchers to dissect complex immune pathways with unrivaled specificity and reproducibility.

• Precision Dissection of TGF-β/Smad3 Signaling in Translat...

  2026-03-16

  SIS3, a selective Smad3 inhibitor from APExBIO, is redefining the landscape of TGF-β/Smad signaling research. This thought-leadership article offers a mechanistic deep-dive into Smad3’s role in fibrosis, renal disease, and cancer, highlights SIS3’s unique experimental and translational advantages, and provides actionable guidance for researchers seeking to bridge preclinical discovery and clinical innovation. Anchored by recent evidence—including the pivotal LUAD study by Zhang et al.—and building upon the current literature, we chart a strategic vision for the next frontier in fibrosis and disease modeling.

• Gap19: Selective Connexin 43 Hemichannel Blocker for Neur...

  2026-03-16

  Gap19 is a selective connexin 43 hemichannel inhibitor peptide with robust neuroprotective and anti-inflammatory actions, supporting its use in stroke and immune modulation research. Its selective mechanism targets Cx43 hemichannels without affecting gap junctions, enabling precise control of neuroglial and macrophage signaling. APExBIO supplies Gap19 (SKU B4919), validated for reproducibility and specificity.

514 records 9/35 page Previous Next First page 上5页 678910 下5页 Last page